Key Highlights

  • Third quarter 2026 Revenue was USD 8.3 million, up 12% from USD 7.4 million a year earlier, with consumables up 24% to USD 4.7 million and instruments up 29% to USD 2.1 million.
  • Flowcells sold reached 9,870, up about 18% from 8,390 a year earlier, which management called a record for any quarter, while the installed base of OGM systems grew about 4% to 398.
  • Net loss narrowed to USD 6.5 million from USD 8.5 million, and gross Margin was 48% against 46%, as operating expenses fell 12% to USD 10.5 million.
  • The company ended the quarter with USD 8.7 million of cash, cash equivalents and securities, and the filing states substantial doubt about its ability to continue as a going concern.

Consumables and Instruments Lift Third Quarter Revenue

Bionano Genomics (NASDAQ:BNGO) filed its Quarterly Report on November 10, 2026 and held its Earnings Call the same day, reporting third quarter 2026 revenue of USD 8.3 million, up 12%. Product revenue was USD 7.8 million, while service and other revenue was USD 0.4 million. The company makes optical genome mapping systems, diagnostic services and software that let labs analyze structural variants in DNA. Consumable revenue rose 24% on more flowcells and a higher average selling price, and instrument revenue rose 29%. Software revenue fell 31% to USD 1.1 million on fewer VIA licenses sold. By region, EMEA revenue was USD 4.1 million, the Americas USD 3.8 million, and Asia Pacific only USD 0.3 million.

Margins Improve While the Net Loss Narrows

Gross margin was 48% against 46%, helped by a mix shift toward higher-margin consumables, and product gross margin reached 53% versus 45%. Selling, general and administrative expense fell 18% to USD 7.4 million, while Research and Development rose 7% to USD 3.0 million. Net loss for the quarter was USD 6.5 million (GAAP), against USD 8.5 million, and the nine-month net loss was USD 22.2 million versus USD 18.5 million. Management said adjusted Operating Expense was USD 8.8 million and that it expects the trends to carry the company toward adjusted EBITDA neutrality by the end of 2027. On the call, management also reiterated full-year 2026 revenue guidance of USD 31 million to USD 33 million, landing near the midpoint.

Going Concern Language and Supply Constraints Frame the Risk

The filing says recurring losses and the need to raise Capital create substantial doubt about the ability to continue as a Going Concern within 12 months. Cash and cash equivalents were USD 4.4 million, with USD 3.8 million of short-term investments and USD 0.5 million restricted, and the USD 10.3 million of debentures was redeemed after the May 2026 maturity. Management said the board may weigh debt, equity, combinations or a sale, and warned of Insolvency relief if funding is not raised. On the call, management said silicon wafer supply limited flowcell output and plans to double capacity by mid-2027. A proposed Medicare coverage determination for OGM in hematologic cancers awaits a final decision.

Where Things Stand

Record flowcell sales show Demand is growing, but they do not yet settle the going concern question. Bionano Genomics (NASDAQ:BNGO) cut its quarterly net loss to USD 6.5 million and lifted gross margin to 48%, yet it held only USD 8.7 million of cash and securities and described a need for additional capital in the very near term. Next markers are the final Medicare coverage decision, any financing or strategic transaction, supply capacity easing by year end, and whether fourth quarter revenue lands near the midpoint of the USD 31 million to USD 33 million guidance.